John O'Malley
LinkedIn Copy
Hey John — congrats on launching Ironleaf. came from a similar path (IB → growth equity) and been thinking a lot about healthcare origination. would be good to connect.
Hey John, looks like we share a similar IB → PE path, though I was in London at Greenhill not working healthcare deals at Edgemont like you. origination was always the same story for me — clear thesis, decent relationships, but no proprietary system of record. the people, tools and ideas were never really connected. every deal virtually sourced from scratch, nothing compounding over time. curious if that's still how most funds operate or if I'm behind the times? — Russ
Hey John, looks like we came up through a similar IB → PE path, though I was in London doing growth deals at Greenhill not in NYC working healthcare M&A at Edgemont. the pattern I keep seeing with most funds is weirdly consistent — strong thesis, solid network, but no proprietary system of record. the people, tools and ideas are never really connected, so every deal is virtually sourced from scratch. nothing compounds on itself. curious if that resonates or if you guys are building something different at Ironleaf given you're standing it up from scratch? — Russ
hey John — no worries if the timing's off. most funds I talk to have tried some version of building origination in-house — analyst pulling from Pitchbook or Grata, maybe using ChatGPT to help qualify, dumping it into a spreadsheet. each piece kind of works, but there's no system of record tying it together. tonnes of wasted energy and everything ends up out of sync. been helping a few funds like Noble Rock work through that. curious if you've run into the same thing standing up Ironleaf? — Russ
totally get it if origination infrastructure isn't top of mind right now — you guys are early and there's probably 10 things ahead of it on the list. the funds I've seen crack it early just tend to compound deal flow in a way that's hard to replicate later. if it ever moves up the list, I'm easy to find. — Russ
Email Copy
John — hope you had a good weekend. wanted to reach out — congrats on launching Ironleaf, always impressed by those who've taken the leap. though we share an IB/PE background (you at Edgemont, me CS/Greenhill), I hope to one day do the same. in the meantime I've been working on the origination side with funds like Axiom Equity and Noble Rock — curious how you're thinking about origination at Ironleaf. mostly proprietary or still seeing a lot through brokers? very best, Russell linkedin.com/in/russellt23
Prospect Research
## PROSPECT INFORMATION: Name: John O'Malley Title: Vice President Fund: Ironleaf Capital Background: PROSPECT SUMMARY: John O'Malley CURRENT ROLE & FOCUS: John is currently a Vice President and founding team member at Ironleaf Capital (ILC), a New York-based healthcare private equity firm. He joined in June 2025 to help scale sustainable, tech-enabled healthcare care models aimed at improving patient outcomes and reducing costs. He recently highlighted a strategic partnership between Ironleaf and New Catalyst Strategic Partners. PROFESSIONAL BACKGROUND: Prior to joining Ironleaf Capital, John spent over four years at Great Point Partners, rising from Associate to Vice President. During his tenure there, he focused on healthcare private equity and managed a portfolio including companies like VetnCare, Ephicacy Consulting Group, and E-Therapy. He began his professional career as an Investment Banking Analyst at Edgemont Partners (2019–2021), where he worked on significant healthcare M&A transactions, including the $1.4 billion purchase of Help at Home by Centerbridge and Vistria. EDUCATION & SKILLS: He holds a BA in Economics and a Master's in Finance from Claremont McKenna College (2019), where he was the Varsity Baseball Team Captain. His technical expertise includes financial modeling, Mergers & Acquisitions, STATA, and healthcare-specific investment analysis. RECENT POSTS & QUOTES: - November 12, 2025: Reposted T.J. Rose regarding a major firm milestone: "This collaboration represents an important step in Ironleaf’s growth and reinforces our mission to back healthcare companies that are improving outcomes, enhancing patient experience, and driving efficiency through technology." - June 24, 2025: Announced his move to Ironleaf Capital: "I’m happy to share that I’m starting a new position as Vice President on the founding team of Ironleaf Capital. Founded by Managing Partner, T.J. Rose, ILC is a purpose-built healthcare private equity firm focused on scaling sustainable, tech-enabled care models." - February 25, 2025: Welcomed a new executive to a portfolio company: "Very excited to welcome Tara Gladwell as CEO of Ephicacy. The Company is primed to continue on its strong growth trajectory under Tara’s leadership." - January 28, 2025: Shared news on leadership changes at VetnCare: "Very excited to welcome Matthew Kirchner as CEO of our growing VetnCare team." - May 6, 2024: Celebrated an acquisition: "Congrats to the Ephicacy and ARA teams. This combination expands Ephicacy’s global Biostatistics and Data Management offering." Fund details: - Description: We partner with founders and management teams to build market-leading tech-enabled businesses that improve the efficiency, cost, and quality of healthcare. Please visit our website to learn more: www.ironleafcapital.com or email us at info@ironleafcapital.com. - Website: https://ironleafcapital.com/ - Location: New York, New York, United States - Lead qualification: Research: - Query: =Ironleaf Capital John O'Malley recent investments fund thesis - Answer: Ironleaf Capital focuses on healthcare IT and tech-enabled solutions, targeting control investments to improve efficiency and reduce costs. John O'Malley is a Vice President, emphasizing strategic partnerships and operational transformation. The firm's investment thesis leverages technology to address industry challenges.